Study at the Man of the Profile of Chimiokines in the Anorexia Bound to the Cancerous Cachexy (CHIMIOKINES)

This is an interventional basic science trial for Cancer of the Pancreas Read More

Group 1 {cancer of the pancreas WITH syndrome of anorexia-cachexie}

Inclusion Criteria:

• Patient to hospitalize in the unit of digestive cancer research.
• Patient ≥ 18 years.
• Patient carrier of an adénocarcinome of the pancreas of novo, any stadium confused, diagnosed by imaging and/or histology.
• Existence of at least one of the criteria following to hold(retain) the diagnosis of cachexie cancer patient: not deliberate loss of weight > in 5 % over the last 6 months OR(WHERE) IMC(CEREBRAL-MOTOR HANDICAPPED) < 20 kg / m ² with a loss of minimum weight > 2 % OR(WHERE) scrawny muscular index appendiculaire respectively < 7,26 kg / m ² at the man and < 5,45 kg / m ² at the woman with a minimal weight loss > 2 %.
• Patient having signed the enlightened consent.

Exclusion Criteria:

• Patient having a tumor other one than the pancreatic adénocarcinome.
• Patient having a second offense of adénocarcinome pancreatic.
• Patient carrier of a pancreatic adénocarcinome in the course of a treatment by chemotherapy.
• Patient having a severe psychiatric comorbidity except TCA who can be responsible for food disorders.
• Patient carrier of an evolutionary inflammatory disease other one than the cancer being able to interfere on the inflammatory status.

Groupe 2 {cancer du pancréas SANS syndrome d'anorexie-cachexie}

Inclusion Criteria:

• Patient to hospitalize in the(unit) of digestive cancer research.
• Patient ≥ 18 years.
• Patient carrier of an adénocarcinome of the pancreas of novo, any stadium confused, diagnosed by imaging and/or histology.
• Patient having signed a enlightened consent.

Exclusion Criteria:

• Patient having a tumor other one than the pancreatic adénocarcinome.
• Patient having a second offense(recurrence) of adénocarcinome pancreatic.
• Patient carrier of a pancreatic adénocarcinome in the course of a treatment by chemotherapy.
• Existence of at least one of the criteria in favour of the diagnosis of cachexie cancer patient: not deliberate loss of weight > in 5 % over the last 6 months OR(WHERE) IMC(CEREBRAL-MOTOR HANDICAPPED) < 20 kg / m ² with a loss of minimum weight > 2 % OR(WHERE) scrawny muscular index appendiculaire respectively < 7,26 kg / m ² at the man and < 5,45 kg / m ² at the woman with a minimal weight loss > 2 %.
• Patient having a severe psychiatric comorbidity except TCA who can be responsible for food disorders.
• Patient carrier of an evolutionary inflammatory disease other one than the cancer being able to interfere on the inflammatory status.
• Patient refusing to participate in the study
• Under guardianship patient or guardianship.

Group 3 {pure food limitation typifies restrictive anorexia nervosa}

Inclusion Criteria:

• Patient seen in consultation in the unit of nutritional support(medium)
• Patient ≥ 18 years.
• Patient carrier of an eating disorder of type pure restrictive anorexia nervosa (according to criterion diagnosis of the WHO)
• Patient having signed a enlightened consent.

Exclusion Criteria:

• Patient having any evolutionary organic pathology source of a decrease of the oral contributions and/or the interference on the inflammatory status, and responsible for a loss of weight
• Patient refusing to participate in the study
• Under guardianship patient or guardianship.

Group 4 {unhurt individual of any appetite-suppressing evolutionary disease and cachectisante}

Inclusion Criteria:

• Patient seen in consultation of hepatogastroenterology
• Patient ≥ 18 years.
• Unhurt patient of any organic or psychic, evolutionary pathology, cachectisante
• Patient having signed a enlightened consent.

Exclusion Criteria:

• Patient refusing to participate in the study
• Under guardianship patient or guardianship.